Hedge Fund ADAR1 Capital Management Invests $36 Million in Denali Therapeutics Following FDA Approval
ADAR1 Capital Management disclosed a significant investment of approximately $36 million into Denali Therapeutics (NASDAQ:DNLI) during the first quarter of 2026, following its first FDA approval. The hedge fund increased its stake by acquiring 1,819,339 shares, raising its position to 2.12% of ADAR1’s reported equity assets.
Tickers: $ABVX $DNLI $PTGX $ROIV
Topics: biotech FDA approval hedge_fund SEC filing